Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer - PubMed
- ️Tue Jan 01 2008
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
Khalid I Al-Shibli et al. Clin Cancer Res. 2008.
Abstract
Purpose: The major value of prognostic markers in potentially curable non-small cell lung cancer (NSCLC) should be to guide therapy after surgical resection. In this regard, the patients' immune status at the time of resection may be important and also measurable. The immune system has paradoxical roles during cancer development. However, the prognostic significance of tumor-infiltrating lymphocytes is controversial. The aim of this study is to elucidate the prognostic significance of epithelial and stromal lymphocyte infiltration in NSCLC.
Experimental design: Tissue microarrays from 335 resected NSCLC, stage I to IIIA were constructed from duplicate cores of viable and representative neoplastic epithelial and stromal areas. Immunohistochemistry was used to evaluate the epithelial and stromal CD4+, CD8+, and CD20+ lymphocytes.
Results: In univariate analyses, increasing numbers of epithelial CD8+ (P = 0.023), stromal CD8+ (P = 0.002), epithelial CD20+ (P = 0.023), stromal CD20+ (P < 0.001), and stromal CD4+ (P < 0.001) lymphocytes correlated significantly with an improved disease-specific survival. No such relation was noted for epithelial CD4+ cells. Furthermore, a low level of stromal CD8+ lymphocyte infiltration was associated with an increased incidence of angiolymphatic invasion (P = 0.032). In multivariate analyses, a high number of stromal CD8+ (P = 0.043) and CD4+ (P = 0.002) cells were independent positive prognostic factors for disease-specific survival.
Conclusions: High densities of CD4+ and CD8+ lymphocytes in the stroma are independent positive prognostic indicators for resected NSCLC patients. This may suggest that these cells are mediating a strong antitumor immune response in NSCLC.
Similar articles
-
Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT. Al-Shibli K, et al. APMIS. 2010 May;118(5):371-82. doi: 10.1111/j.1600-0463.2010.02609.x. APMIS. 2010. PMID: 20477813
-
Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. Al-Shibli K, et al. Histopathology. 2009 Sep;55(3):301-12. doi: 10.1111/j.1365-2559.2009.03379.x. Histopathology. 2009. PMID: 19723145
-
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A. Kawai O, et al. Cancer. 2008 Sep 15;113(6):1387-95. doi: 10.1002/cncr.23712. Cancer. 2008. PMID: 18671239
-
[Prognostic value of CD4+ pleural cavity lymphocytes in non-small cell lung cancer].
Takahashi K. Takahashi K. Nihon Rinsho. 2002 May;60 Suppl 5:272-5. Nihon Rinsho. 2002. PMID: 12101671 Review. Japanese. No abstract available.
-
Inflammatory cell infiltration of tumors: Jekyll or Hyde.
Talmadge JE, Donkor M, Scholar E. Talmadge JE, et al. Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400. doi: 10.1007/s10555-007-9072-0. Cancer Metastasis Rev. 2007. PMID: 17717638 Review.
Cited by
-
Liao Y, Ni Y, He R, Liu W, Du J. Liao Y, et al. J Cancer Res Clin Oncol. 2013 Sep;139(9):1523-8. doi: 10.1007/s00432-013-1471-8. Epub 2013 Jul 9. J Cancer Res Clin Oncol. 2013. PMID: 23835897
-
Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T. Hald SM, et al. BMC Cancer. 2015 May 29;15:441. doi: 10.1186/s12885-015-1446-z. BMC Cancer. 2015. PMID: 26021984 Free PMC article.
-
Zhu S, Han X, Qiao X, Chen S. Zhu S, et al. Front Oncol. 2020 Aug 14;10:1330. doi: 10.3389/fonc.2020.01330. eCollection 2020. Front Oncol. 2020. PMID: 32923385 Free PMC article.
-
ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW.
Yoshimoto Y, Kono K, Suzuki Y. Yoshimoto Y, et al. Fukushima J Med Sci. 2015;61(1):13-22. doi: 10.5387/fms.2015-6. Epub 2015 Jul 2. Fukushima J Med Sci. 2015. PMID: 26135666 Free PMC article. Review.
-
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Senovilla L, et al. Oncoimmunology. 2012 Nov 1;1(8):1323-1343. doi: 10.4161/onci.22009. Oncoimmunology. 2012. PMID: 23243596 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials